ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 527 for:    Recruiting, Not yet recruiting, Available Studies | "Platelet Aggregation Inhibitors"

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS (STOPDAPT-2 ACS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03462498
Recruitment Status : Recruiting
First Posted : March 12, 2018
Last Update Posted : April 11, 2018
Sponsor:
Information provided by (Responsible Party):
Takeshi Morimoto, Kyoto University, Graduate School of Medicine

Brief Summary:
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS).

Condition or disease Intervention/treatment Phase
Acute Coronary Syndrome Acute Myocardial Infarction Coronary Artery Disease Percutaneous Coronary Intervention Platelet Aggregation Inhibitors Drug: 1-months DAPT Drug: 12-month DAPT Phase 4

Detailed Description:
The drug-eluting stents (DESs) are currently used in the majority of percutaneous coronary intervention (PCI) procedures. On the other hand, the problems of the first-generation DES (late adverse events, such as very late stent thrombosis) have been pointed out. Dual antiplatelet therapy (DAPT) has become a standard regimen after DES implantation and for fear of very late stent thrombosis, DAPT is frequently performed for 1 year or longer in clinical practice. Especially guidelines recommend 1-year DAPT for patients with acute coronary syndrome (ACS), though its rational is based on the study more than 15 years old. However, serious hemorrhagic complications associated with prolonged DAPT duration can bring disadvantages to patients, and it is extremely important to clarify an optimal DAPT duration after DES procedure. Currently, 1-month DAPT regimen after bare metal stent (BMS) implantation is commonly used in clinical practice, producing no major problems. Based on a meta-analysis of recent clinical studies, it has also been reported that the use of Cobalt-Chromium Everolimus-Eluting Stent (CoCr-EES) reduces the risk of early stent thrombosis by half compared to the use of BMS. There is no necessity to extend antiplatelet therapy after CoCr-EES implantation longer than after BMS implantation, and it is considered possible to use the same 1-month DAPT duration as after BMS implantation. The investigators already planned and started a multicenter, randomized, open-label, controlled study, in which the subjects who have undergone CoCr-EES procedure will be divided into the 1-month DAPT and clopidogrel monotherapy group and the 12-month DAPT and aspirin monotherapy group (STOPDAPT-2; NCT02619760), where primary endpoint is the incidence of composite events including cardiovascular death, myocardial infarction, stent thrombosis, stroke, and bleeding defined by TIMI major or minor bleeding. In STOPDAPT-2, the non-inferiority about primary endpoint of 1-month DAPT group will be evaluated at 12 months after index procedure and secondarily, the superiority about primary endpoint of 1-month DAPT group will be evaluated at 5 years after index procedure. The proportion of patients with ACS is about 30-40% in STOPDAPT-2 and the power is insufficient to evaluate the safety and efficacy of 1-month DAPT regimen specifically for patients with ACS. Therefore the investigators planned the current study to enroll patients of ACS with the same protocol as STOPDAPT-2.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 3000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Study to Evaluate the Safety of Reducing Dual Antiplatelet Therapy (DAPT) Duration to 1 Month for Patients With Acute Coronary Syndrome (ACS) After Implantation of Everolimus-eluting Cobalt-chromium Stent
Actual Study Start Date : April 2, 2018
Estimated Primary Completion Date : March 31, 2025
Estimated Study Completion Date : March 31, 2026

Arm Intervention/treatment
Active Comparator: 1-month DAPT
1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists and clopidogrel monotherapy for 59 months
Drug: 1-months DAPT
1-month DAPT followed by 59-month monotherapy

Active Comparator: 12-month DAPT
1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists; 11-month DAPT composed of aspirin and clopidogrel and aspirin monotherapy for 48 months
Drug: 12-month DAPT
12-month DAPT followed by 48-month monotherapy




Primary Outcome Measures :
  1. Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke/bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group [ Time Frame: 12 months ]
  2. Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke/bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group [ Time Frame: 60 months ]

Secondary Outcome Measures :
  1. Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke [ Time Frame: 12 months ]
  2. Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke [ Time Frame: 60 months ]
  3. Bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group [ Time Frame: 12 months ]
  4. Bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group [ Time Frame: 60 months ]
  5. Upper gastrointestinal endoscopic examination or treatment [ Time Frame: 60 months ]
  6. Composite event of all-cause death/myocardial infarction [ Time Frame: 12 months ]
  7. Composite event of all-cause death/myocardial infarction [ Time Frame: 60 months ]
  8. All-cause death [ Time Frame: 12 months ]
  9. All-cause death [ Time Frame: 60 months ]
  10. Composite event of cardiovascular death/myocardial infarction [ Time Frame: 12 months ]
  11. Composite event of cardiovascular death/myocardial infarction [ Time Frame: 60 months ]
  12. Cardiovascular death [ Time Frame: 12 months ]
  13. Cardiovascular death [ Time Frame: 60 months ]
  14. Myocardial infarction [ Time Frame: 12 months ]
  15. Myocardial infarction [ Time Frame: 60 months ]
  16. Stroke [ Time Frame: 12 months ]
  17. Stroke [ Time Frame: 60 months ]
  18. Definite stent thrombosis [ Time Frame: 12 months ]
    Academic Research Consortium definition

  19. Definite stent thrombosis [ Time Frame: 60 months ]
    Academic Research Consortium definition

  20. Target lesion failure [ Time Frame: 12 months ]
  21. Target lesion failure [ Time Frame: 60 months ]
  22. Target vessel failure [ Time Frame: 12 months ]
  23. Target vessel failure [ Time Frame: 60 months ]
  24. Major adverse cardiac event [ Time Frame: 12 months ]
    Composite of cardiac death, myocardial infarction, and clinically-driven TLR

  25. Major adverse cardiac event [ Time Frame: 60 months ]
    Composite of cardiac death, myocardial infarction, and clinically-driven TLR

  26. Target lesion revascularization [ Time Frame: 12 months ]
  27. Target lesion revascularization [ Time Frame: 60 months ]
  28. Clinically-driven target lesion revascularization [ Time Frame: 12 months ]
  29. Clinically-driven target lesion revascularization [ Time Frame: 60 months ]
  30. Non target lesion revascularization [ Time Frame: 12 months ]
  31. Non target lesion revascularization [ Time Frame: 60 months ]
  32. Coronary artery bypass graft [ Time Frame: 12 months ]
  33. Coronary artery bypass graft [ Time Frame: 60 months ]
  34. Target vessel revascularization [ Time Frame: 12 months ]
  35. Target vessel revascularization [ Time Frame: 60 months ]
  36. Any coronary revascularization [ Time Frame: 12 months ]
  37. Any coronary revascularization [ Time Frame: 60 months ]
  38. Bleeding complications [ Time Frame: 12 months ]
  39. Bleeding complications [ Time Frame: 60 months ]
  40. Gastrointestinal bleeding [ Time Frame: 12 months ]
  41. Gastrointestinal bleeding [ Time Frame: 60 months ]
  42. Gastrointestinal complaints requiring upper gastrointestinal endoscopy [ Time Frame: 12 months ]
  43. Gastrointestinal complaints requiring upper gastrointestinal endoscopy [ Time Frame: 60 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients received percutaneous coronary intervention with cobalt-chromium everolimus-eluting stent under the setting of acute coronary syndrome
  • Patients who are capable of oral dual antiplatelet therapy consisting of aspirin and P2Y12 receptor antagonist

Exclusion Criteria:

  • Patients requiring oral anticoagulants
  • Patients with medical history of intracranial hemorrhage
  • Patients who have experienced serious complications (myocardial infarction, stroke, and major bleeding) during hospital stay after percutaneous coronary intervention
  • Patients with drug eluting stents other than Cobalt chromium everolimus eluting stents implanted at the time of enrollment
  • Patients confirmed to have no tolerability to clopidogrel before enrollment
  • Patients requiring continuous administration of antiplatelet drugs other than aspirin and P2Y12 receptor antagonists at the time of enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03462498


Contacts
Contact: Takeshi Kimura, MD +81-75-751-4254 taketaka@kuhp.kyoto-u.ac.jp
Contact: Takeshi Morimoto, MD, PhD, MPH +81-798-45-6879 morimoto@kuhp.kyoto-u.ac.jp

Locations
Japan
Kyoto University Graduate School of Medicine Recruiting
Kyoto, Japan, 606-8507
Contact: Takeshi Kimura, MD    +81-75-751-4254    taketaka@kuhp.kyoto-u.ac.jp   
Contact: Hirotoshi Watanabe, MD    +81-75-751-4255    hwatanab@kuhp.kyoto-u.ac.jp   
Principal Investigator: Takeshi Kimura, MD         
Sponsors and Collaborators
Kyoto University, Graduate School of Medicine
Investigators
Principal Investigator: Takeshi Kimura, MD Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Responsible Party: Takeshi Morimoto, Professor of Medicine, Kyoto University, Graduate School of Medicine
ClinicalTrials.gov Identifier: NCT03462498     History of Changes
Other Study ID Numbers: C1348
First Posted: March 12, 2018    Key Record Dates
Last Update Posted: April 11, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Takeshi Morimoto, Kyoto University, Graduate School of Medicine:
Acute Coronary Syndrome
Acute Myocardial Infarction
Coronary Artery Disease
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors

Additional relevant MeSH terms:
Platelet Aggregation Inhibitors
Syndrome
Infarction
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Myocardial Infarction
Acute Coronary Syndrome
Disease
Pathologic Processes
Ischemia
Necrosis
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs